Seysara FDA Approval History
Seysara (sarecycline) is an oral, narrow spectrum tetracycline-derived antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Development Timeline for Seysara
|Oct 2, 2018||FDA Approves Seysara (sarecycline) for the Treatment of Moderate to Severe Acne|
|Dec 20, 2017||FDA Accepts New Drug Application for Seysara (sarecycline) for the Treatment of Moderate to Severe Acne|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.